C43.1
Malignant melanoma of eyelid, including canthus
Clinical Classification Guidelines
Medical Intelligence & Overview
Malignant melanoma of the eyelid, classified under ICD-10 code C43.1, is a serious form of skin cancer that originates from melanocytes—the cells responsible for pigment production. Although it constitutes a small percentage of eyelid cancers, its aggressive nature warrants prompt recognition and treatment. This condition affects the eyelid region, including the inner canthus (the corner where the upper and lower eyelids meet). Early diagnosis and management are crucial to prevent spread and preserve vision and eye health.
Causes & Symptoms
Clinical Causes: Prolonged and unprotected exposure to ultraviolet (UV) radiation from the sun or artificial sources. Genetic predisposition, especially in individuals with a family history of melanoma or other skin cancers. Presence of atypical or dysplastic moles that may transform into melanoma over time. History of frequent skin injuries or chronic skin inflammation in the eyelid area. Immune system suppression, which may increase susceptibility to skin cancers. Fair skin, light hair, and light eye color, which are associated with higher risk. Exposure to certain chemicals or environmental factors that may contribute to skin mutations.
Key Symptoms: A new or changing pigmented lesion on the eyelid or canthus area. A mole or growth that becomes irregular in shape, color, or size. Asymmetrical lesions with uneven borders. Colors that vary within the lesion, such as shades of brown, black, blue, or black discoloration. Eyelid swelling or irritation that persists. Ulceration or bleeding from a pigmented lesion. Persistent redness or crusting in the affected area. Sensations of itchiness, tenderness, or pain localized to the lesion.
Diagnostic & Treatment
Diagnosis Path: Diagnosis typically involves a comprehensive physical examination of the eyelid and surrounding skin. The dermatologist or ophthalmologist may perform the following steps: - **Visual assessment**: Evaluating the lesion's size, shape, color, and borders. - **Dermoscopy**: A specialized magnifying technique to examine pigmented areas more closely. - **Biopsy**: Removal of a tissue sample for histopathological analysis to confirm melanoma and determine its stage. - **Imaging tests**: Such as ultrasound, MRI, or CT scans to assess local invasion or metastasis if indicated. Early and accurate diagnosis guides appropriate treatment planning and improves outcomes.
Treatment Protocols: Treatment strategies for malignant melanoma of the eyelid generally involve a multidisciplinary approach and may include: - **Surgical excision**: Complete removal of the tumor with clear margins, often using Mohs micrographic surgery for tissue conservation. - **Reconstruction**: Repair of the eyelid using grafts or local flaps to preserve function and appearance after tumor removal. - **Adjuvant therapy**: Depending on the stage, options may include radiation therapy, immunotherapy, or targeted systemic treatments. - **Monitoring**: Regular follow-up examinations to detect any recurrence or new primary melanomas. The choice of treatment depends on tumor size, depth, location, and whether it has spread beyond the eyelid.
Clinical Advice & FAQs
Billing Guidance
Is C43.1 a billable ICD-10 code?
Yes, C43.1 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report C43.1?
Clinical documentation must specify the nature of Malignant melanoma of eyelid, including canthus and any associated comorbidities for accurate reporting.
Cite this Clinical Reference
